Overview

A Study of LY3209590 Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Status:
Not yet recruiting

Trial end date:
2024-04-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effect and safety of LY3209590 compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. Additional participants will continue to be enrolled in a maximum extended enrollment cohort.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin